BCL2 and acute myeloid leukemia: Our results highlight that using TRIB2 as a biomarker, we can identify AML cells with a heightened sensitivity to combined BCL2 inhibition and chemotherapy, thus providing a novel therapeutic approach for treating TRIB2+ AML.